Regorafenib dose modifications in patients with metastatic colorectal cancer in the phase III CORRECT study

被引：0
|
作者：
Falcone, A. [1 ]
Van Cutsem, E. [2 ]
Sobrero, A. [3 ]
Siena, S. [4 ]
Ychou, M. [5 ]
Lenz, H. J. [6 ]
Yoshino, T. [7 ]
Cihon, F.
Wagner, A. [8 ]
Grothey, A. [9 ]
机构：
[1] Azienda Osped Univ Pisana, UO Oncol Med, Pisa, Italy
[2] Katholieke Univ Leuven Hosp, Louvain, Belgium
[3] Osped San Martino Genova, Genoa, Italy
[4] Osped Niguarda Ca Granda, Milan, Italy
[5] ICM Val dAurelle, Montpellier, France
[6] VSC Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Chiba, Japan
[8] Bayer Pharma AG, Global Clin Dev Oncol, Berlin, Germany
[9] Mayo Clin, Dept Oncol, Rochester, MN USA
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2360
引用
收藏
页码：S546 / S546
页数：1
相关论文
共 50 条
  • [21] Regorafenib dose escalation therapy for patients with refractory metastatic colorectal cancer (RECC Study)
    Nakamura, Masato
    Yamada, Takeshi
    Ishiyama, Shun
    Enomoto, Masanobu
    Yokomizo, Hajime
    Kosugi, Chihiro
    Sonoda, Hiromichi
    Ishimaru, Kei
    Ishibashi, Keiichiro
    Kuramochi, Hidekazu
    Nozawa, Keijiro
    Ohta, Ryo
    Takahashi, Makoto
    Yoshida, Hiroshi
    Hashiguchi, Yojiro
    Hirata, Keiji
    Katsumata, Kenji
    Ishida, Hideyuki
    Koda, Keiji
    Sakamoto, Kazuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [22] Regorafenib dose escalations in the prospective, observational CORRELATE study in patients with metastatic colorectal cancer
    Ducreux, M.
    O'Connor, J.
    Dochy, E.
    Fiala-Buskies, S.
    Cervantes, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 119 - 119
  • [23] Time to health status deterioration in regorafenib-treated patients with metastatic colorectal cancer (mCRC): A post-hoc analysis of the phase III CORRECT study
    Chang, J.
    Pawar, V.
    Grothey, A.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Wagner, A.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S546 - S546
  • [24] Time to health status deterioration in regorafenib-treated patients with metastatic colorectal cancer (mCRC): a post-hoc analysis of the phase III CORRECT study
    Stein, A.
    Pawar, V.
    Grothey, A.
    Sobrero, A.
    Siena, S.
    Falcone, A.
    Ychou, M.
    Lenz, H. J.
    Yoshino, T.
    Wagner, A.
    van Cutsem, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 40 - 40
  • [25] Characteristics and outcomes of patients enrolled in the CORRECT and CONCUR phase 3 trials of regorafenib for metastatic colorectal cancer (mCRC)
    Vogel, A.
    van Cutsem, E.
    Wagner, A.
    Kalmus, J.
    Qin, S.
    Kim, T. W.
    Li, J.
    Xu, R.
    Grothey, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 71 - 71
  • [26] Pharmacokinetics of regorafenib (REG) in the phase 3 CONCUR and CORRECT trials in patients (pts) with metastatic colorectal cancer (mCRC)
    Cleton, A.
    Sturm, I.
    Trnkova, Z. Jirakova
    Grevel, J.
    Fiala-Buskies, S.
    Lettieri, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 10 - 10
  • [27] Phase II dose titration study of regorafenib for patients with unresectable metastatic colorectal cancer that progressed after standard chemotherapy
    Kudo, Toshihiro
    Kato, Takeshi
    Kagawa, Yoshinori
    Sakai, Daisuke
    Satoh, Taroh
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [28] Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 18 - 19
  • [29] Dose-escalation of REgorafenib for patients with previously treated metastatic colorectal cancer - DEREGULATE study
    Nishitai, Ryuta
    Manaka, Dai
    Amaike, Hisashi
    Nozaki, Akira
    Kanai, Masashi
    Yamaguchi, Daisuke
    Yazawa, Takeshi
    Kawashima, Kazuhiko
    Ikeda, Fusao
    ANNALS OF ONCOLOGY, 2015, 26 : 129 - 130
  • [30] Cavitation of lung metastases induced by regorafenib in patients with colorectal carcinoma: Data from the phase III CORRECT study
    Ricotta, R.
    Verrioli, A.
    Ghezzi, S.
    Grothey, A.
    Cremolini, C.
    Argiles, G.
    Adenis, A.
    Ychou, M.
    Barone, C.
    Bouchet, O.
    Humblet, Y.
    Mineur, L.
    Sobrero, A.
    Peeters, M.
    Van Cutsem, E.
    Porcu, L.
    Amatu, A.
    Sartore-Bianchi, A.
    Vanzulli, A.
    Siena, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S333 - S333
12345